Author

E. Zoler

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:host-pathogen & immune response· 2 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

G. Schreiber· 2 shared B. Meyer· 1 shared B. Sun· 1 shared J. Chiaravalli· 1 shared J. Piehler· 1 shared J. S. Bellon· 1 shared J. Zahradnik· 1 shared M. Shemesh· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

G. Schreiber

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Specificity and promiscuity of JAK recruitment regulates pleiotropy of cytokine-receptor signaling

E. Zoler, T. Meyer, J. S. Bellon, B. Sun, J. Piehler, G. Schreiber

The paper investigates JAK recruitment specificity and promiscuity in cytokine-receptor signaling, finding that JAKs can interchangeably bind to receptors, leading to cell type-specific signaling pleiotropy.

bioRxiv · Oct 4, 2023Biochemistry

SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor

J. Zahradnik, S. Marciano, M. Shemesh, E. Zoler, J. Chiaravalli, B. Meyer, Y. Rudich, O. Dym, N. Elad, G. Schreiber

The paper shows that in vitro evolved SARS-CoV-2 RBD mutations, like S477N, E484K, and N501Y, correlate with increased infectivity and are inhibited by high-affinity RBD drugs.

bioRxiv · Jan 6, 2021Biochemistry